Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Armand, Philippe; Rodig, Scott; Melnichenko, Vladimir; Thieblemont, Catherine; Bouabdallah, Kamal; Tumyan, Gayane; ÖZCAN, MUHİT; Portino, Sergio; Fogliatto, Laura; Caballero, Maria; Walewski, Jan; Gulbas, Zafer; Ribrag, Vincent; Christian, Beth; Perini, Guilherme; Salles, Gilles; Svoboda, Jakub; Zain, Jasmine; Patel, Sanjay; Chen, Pei-Hsuan; Ligon, Azra; Ouyang, Jing; Neuberg, Donna; Redd, Robert; Chatterjee, Arkendu; Balakumaran, Arun; Orlowski, Robert; Shipp, Margaret; Zinzani, Pier

doi:10.1200/jco.19.01389

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Copy For Citation

Armand P., Rodig S., Melnichenko V., Thieblemont C., Bouabdallah K., Tumyan G., ...More

JOURNAL OF CLINICAL ONCOLOGY, vol.37, no.34, pp.3291-3301, 2019 (SCI-Expanded)

Publication Type: Article / Article
Volume: 37 Issue: 34
Publication Date: 2019
Doi Number: 10.1200/jco.19.01389
Journal Name: JOURNAL OF CLINICAL ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.3291-3301
Ankara University Affiliated: Yes

Abstract

PURPOSE Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands (PD-L1), it is hypothesized to be susceptible to PD-1 blockade.